SLE関連肺動脈性肺高血圧症における分子状水素の免疫マーカー調節効果：症例報告
A 51-year-old woman with systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH), diagnosed in 2012, experienced progressive deterioration following a sepsis episode in 2018, manifesting as severe dyspnea and oxygen desaturation despite vasodilator therapy. In March 2024, oral hydrogen capsules were introduced as an adjunctive intervention. Subsequent immunological assessment revealed an elevated proportion of Tr1 cells alongside reductions in Treg cell subsets, B cell subsets, marginal zone cells, and plasma cells. Clinical stability was achieved without any recorded adverse events or complications. This case suggests that molecular hydrogen may influence immune cell composition in SLE-PAH with decompensated right-sided heart failure, warranting further investigation into its immunomodulatory mechanisms and clinical applicability.
Oral hydrogen capsule administration was associated with an increased proportion of Tr1 regulatory cells and decreased proportions of Treg subsets, B cell subsets, marginal zone cells, and plasma cells, suggesting modulation of immune cell composition.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/40010970